Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Pharming Group N.V.NASDAQ: PHAR

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $3.13M rose 21.1% year over year, ahead of the -34.4% change in trailing-twelve-month depreciation & amortization.

Context

  • Depreciation & amortization amounted to 0.0% of revenue in FY2025, down 5.4 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +21.1% holds above the trailing-twelve-month pace of -34.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.13M— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$8.54M-34.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.1%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Depreciation & Amortization vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -34.4% is the lowest of 9, against a peer median of +14.2%.
  • Depreciation & amortization amounts to 2.3% of revenue for PHAR, versus a peer median of 15.1%.
PHAR Competitors
Depreciation & Amortization for PHAR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$244.53B USD+295495.6%-7.9%23.8%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$28.19M USD+36.7%+0.9%2.9%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$10.18M USD+0.4%+20.7%—
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$9.99M USD-2.7%+10.7%15.1%
PHARPharming Group N.V.LTM Mar 2026$8.54M USD-34.4%—2.3%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$5.95M USD+365.1%-1.1%0.6%
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.72M EUR-0.9%+1.0%20.3%
STOKStoke Therapeutics, Inc.LTM Mar 2026$2.28M USD+9.0%+4.6%7.1%
SLNSilence Therapeutics plcLTM Mar 2026$885K USD—-2.3%96.0%
PHVSPharvaris N.V.LTM Sep 2026€483K EUR+19.4%+39.9%—
Peer median (excluding PHAR) —+14.2%+1.0%15.1%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income26.16M14.99M(12.01M)(8.79M)2.86M
Depreciation & Amortization22.23M13.19M15.93M16.64M0
Deferred Income Tax00000
Stock-Based Compensation10.27M6.39M9.25M11.65M0
Change in Working Capital(5.62M)(387K)(16.96M)(10.43M)14.4M
Accounts Receivables6.71M2.36M(18.54M)(7.02M)(3.36M)
Inventory(6.98M)(15.02M)(14.43M)(520.85K)(1.29M)
Accounts Payables000017.87M
Other Working Capital(5.36M)12.27M16.01M(2.88M)1.19M
Other Non-Cash Items(10.14M)(11.72M)(13.51M)(10.92M)32.8M
Operating Cash Flow42.9M22.46M(17.3M)(1.86M)50.07M
Capital Expenditures(18.95M)(1.98M)(1.46M)(824.25K)(751.09K)
Acquisitions (Net)07.3M00(65.53M)
Purchases of Investments(5.2M)0(382.01M)(294.4M)0
Sales of Investments00232.81M327.97M0
Other Investing Activities0021.28M084.72M
Investing Cash Flow(24.15M)5.32M(129.39M)32.74M18.43M
Debt Repayment(3.65M)(3.31M)(4.04M)(35.61M)0
Common Stock Issued5.35M2.28M0019.87M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(33.39M)(3.95M)3M(19.67K)(5.39M)
Financing Cash Flow(31.68M)(4.98M)(1.04M)(35.63M)14.48M
Effect of Forex Changes(2.07M)(7.38M)2.13M(2.29M)8.12M
Net Change in Cash(15M)15.42M(145.6M)(7.04M)91.09M
Free Cash Flow23.95M20.48M(18.77M)(2.68M)49.31M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.